Yuichi Sato
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Yuichi Sato has a total of 51 co-authors. Here are the top co-authors by number of shared publications:
Shuji Terai
Division of Gastroenterology and Hepatology, Graduate School of Medical and Dental Sciences, Niigata University, Niigata, Japan
3 shared publicationsManabu Takeuchi
Yuichi Sato, Satoru Hashimoto, Ken-ichi Mizuno, Manabu Takeuchi, Shuji Terai, Department of Gastroenterology, Niigata University Graduate School of Medical and Dental Sciences, Niigata 951-8121, Japan
2 shared publicationsSatoru Hashimoto
Yuichi Sato, Satoru Hashimoto, Ken-ichi Mizuno, Manabu Takeuchi, Shuji Terai, Department of Gastroenterology, Niigata University Graduate School of Medical and Dental Sciences, Niigata 951-8121, Japan
2 shared publicationsAkito Sato
Division of Gastroenterology, Nagaoka Central General Hospital, Nagaoka, Japan
1 shared publication- Atsunori Tsuchiya
Division of Gastroenterology and Hepatology, Graduate School of Medical and Dental Sciences, Niigata University, Niigata, Japan
1 shared publication - Hanako Wakatsuki
Department of Plastic and Reconstructive Surgery, Graduate School of Medical and Dental Sciences, Niigata University, Niigata, Japan
1 shared publication
Latest Publications
- 27 September 2021
- Published by Elsevier in Gastrointestinal Endoscopy
- Vol. 95 (1) , 192-194
Small G1 type III gastric neuroendocrine cell tumor showing scirrhous invasion and lymph node metastasis
- 27 September 2021
- Published by Elsevier in Gastrointestinal Endoscopy
- Vol. 95 (1) , 192-194
Small G1 type III gastric neuroendocrine cell tumor showing scirrhous invasion and lymph node metastasis
- Open Access
- 30 June 2021
- Published by Kurume Medical Journal in The Kurume Medical Journal
- Vol. 68 (2) , 107-113
Influence of Helicobacter Pylori Infection on Hepcidin Expression in the Gastric Mucosa
Summary: Background: Hepcidin is an antimicrobial peptide and a key hormone involved in iron homeostasis. Hepcidin level is elevated in the serum during the course of Helicobacter pylori infection and hepcidin is considered to contribute to iron deficiency anemia. However, it is unclear whether H. pylori infection influences hepcidin expression in the gastric mucosa. Method: In this study, 15 patients with H. pylori-infected nodular gastritis, 43 patients with H. pylori-infected chronic gastritis, and 33 patients without H. pylori infection were enrolled. Endoscopic biopsy, and histological and immunohistochemical analysis were performed to evaluate the expression of hepcidin and its distribution in the gastric mucosa. Result: Hepcidin was strongly expressed in the lymph follicles of patients with nodular gastritis. The detection rates of gastric hepcidin-positive lymphocytes in patients with nodular gastritis and chronic gastritis were significantly higher than that without H. pylori infection. Moreover, regardless of the H. pylori infection status, hepcidin was expressed in the cytoplasm and intracellular canaliculi of gastric parietal cells. Conclusion: Hepcidin is expressed at a steady state in gastric parietal cells, and H. pylori infection may induce hepcidin expression in lymphocytes present in the gastric mucosal lymphoid follicles. This phenomenon may be associated with systemic hepcidin overexpression and iron deficiency anemia in patients with H. pylori-infected nodular gastritis.
- 30 June 2021
- Published by Kurume Medical Journal in The Kurume Medical Journal
- Vol. 68 (2) , 107-113
Open AccessInfluence of Helicobacter Pylori Infection on Hepcidin Expression in the Gastric Mucosa
Summary: Background: Hepcidin is an antimicrobial peptide and a key hormone involved in iron homeostasis. Hepcidin level is elevated in the serum during the course of Helicobacter pylori infection and hepcidin is considered to contribute to iron deficiency anemia. However, it is unclear whether H. pylori infection influences hepcidin expression in the gastric mucosa. Method: In this study, 15 patients with H. pylori-infected nodular gastritis, 43 patients with H. pylori-infected chronic gastritis, and 33 patients without H. pylori infection were enrolled. Endoscopic biopsy, and histological and immunohistochemical analysis were performed to evaluate the expression of hepcidin and its distribution in the gastric mucosa. Result: Hepcidin was strongly expressed in the lymph follicles of patients with nodular gastritis. The detection rates of gastric hepcidin-positive lymphocytes in patients with nodular gastritis and chronic gastritis were significantly higher than that without H. pylori infection. Moreover, regardless of the H. pylori infection status, hepcidin was expressed in the cytoplasm and intracellular canaliculi of gastric parietal cells. Conclusion: Hepcidin is expressed at a steady state in gastric parietal cells, and H. pylori infection may induce hepcidin expression in lymphocytes present in the gastric mucosal lymphoid follicles. This phenomenon may be associated with systemic hepcidin overexpression and iron deficiency anemia in patients with H. pylori-infected nodular gastritis.
- Open Access
- 1 December 2019
- Published by Elsevier in Regenerative Therapy
- Vol. 11, 41-46
Efficacy of gelatin hydrogels incorporating triamcinolone acetonide for prevention of fibrosis in a mouse model
- 1 December 2019
- Published by Elsevier in Regenerative Therapy
- Vol. 11, 41-46
Open AccessEfficacy of gelatin hydrogels incorporating triamcinolone acetonide for prevention of fibrosis in a mouse model
- Open Access
- 1 January 2016
- Published by Baishideng Publishing Group Inc. in World Journal of Gastroenterology
- Vol. 22 (30) , 6817-6828
Management of gastric and duodenal neuroendocrine tumors
Management of gastric and duodenal neuroendocrine tumors
- 1 January 2016
- Published by Baishideng Publishing Group Inc. in World Journal of Gastroenterology
- Vol. 22 (30) , 6817-6828
Open AccessManagement of gastric and duodenal neuroendocrine tumors
Management of gastric and duodenal neuroendocrine tumors
- Open Access
- 1 January 2015
- Published by Baishideng Publishing Group Inc. in World Journal of Gastrointestinal Endoscopy
- Vol. 7 (4) , 346-353
Endoscopic diagnosis and management of type I neuroendocrine tumors
Endoscopic diagnosis and management of type I neuroendocrine tumors
- 1 January 2015
- Published by Baishideng Publishing Group Inc. in World Journal of Gastrointestinal Endoscopy
- Vol. 7 (4) , 346-353
Open AccessEndoscopic diagnosis and management of type I neuroendocrine tumors
Endoscopic diagnosis and management of type I neuroendocrine tumors
- 25 September 2014
- Published by Wiley in Helicobacter
- Vol. 20 (1) , 11-18
The Relationship Between Iron Deficiency in Patients with Helicobacter Pylori‐Infected Nodular Gastritis and the Serum Prohepcidin Level
Background and aims: Helicobacter pylori (H. pylori) is recognized as a causative agent for unexplained iron‐deficiency anemia (IDA). We evaluated many background factors influencing an iron‐deficiency state in adult patients with various H. pylori‐infected upper gastrointestinal tract diseases.Method: Study 1: H. pylori‐infected 121 patients (nodular gastritis (NG) (n = 19), duodenal ulcer (DU) (n = 30), or gastric ulcer (GU) (n = 47), or gastric hyperplastic polyp (GHP) (n = 25)) were enrolled. The RBC count and hemoglobin, iron, ferritin, pepsinogen (PG) I, PG II, gastrin, and anti‐H. pylori antibody (Ab) levels in the serum were measured. Study 2: H. pylori‐infected 105 patients (NG, n = 19; DU, n = 43; GU, n = 32; GHP, n = 11) and non‐H. pylori‐infected individuals (n = 35) were examined for the levels of prohepcidin, ferritin, and iron in the serum. In addition, we measured the data before and after the H. pylori eradication.Results: In the patients with GHP and NG, hypoferritinemia was observed in comparison with the GU and DU patients. In the GHP patients, low levels of PG I, a decreased PG I/II ratio, and hypergastrinemia were observed. The levels of serum prohepcidin in the patients with H. pylori‐associated disease were higher than those in the uninfected adults. In the patients with NG, the serum prohepcidin levels were higher than those in the other H. pylori‐infected patient groups and decreased after the eradication.Conclusion: H. pylori‐related iron‐deficiency state might be associated with several factors, such as hypochlorhydria and hepcidin, in patients with GHP or NG.
- 25 September 2014
- Published by Wiley in Helicobacter
- Vol. 20 (1) , 11-18
The Relationship Between Iron Deficiency in Patients with Helicobacter Pylori‐Infected Nodular Gastritis and the Serum Prohepcidin Level
Background and aims: Helicobacter pylori (H. pylori) is recognized as a causative agent for unexplained iron‐deficiency anemia (IDA). We evaluated many background factors influencing an iron‐deficiency state in adult patients with various H. pylori‐infected upper gastrointestinal tract diseases.Method: Study 1: H. pylori‐infected 121 patients (nodular gastritis (NG) (n = 19), duodenal ulcer (DU) (n = 30), or gastric ulcer (GU) (n = 47), or gastric hyperplastic polyp (GHP) (n = 25)) were enrolled. The RBC count and hemoglobin, iron, ferritin, pepsinogen (PG) I, PG II, gastrin, and anti‐H. pylori antibody (Ab) levels in the serum were measured. Study 2: H. pylori‐infected 105 patients (NG, n = 19; DU, n = 43; GU, n = 32; GHP, n = 11) and non‐H. pylori‐infected individuals (n = 35) were examined for the levels of prohepcidin, ferritin, and iron in the serum. In addition, we measured the data before and after the H. pylori eradication.Results: In the patients with GHP and NG, hypoferritinemia was observed in comparison with the GU and DU patients. In the GHP patients, low levels of PG I, a decreased PG I/II ratio, and hypergastrinemia were observed. The levels of serum prohepcidin in the patients with H. pylori‐associated disease were higher than those in the uninfected adults. In the patients with NG, the serum prohepcidin levels were higher than those in the other H. pylori‐infected patient groups and decreased after the eradication.Conclusion: H. pylori‐related iron‐deficiency state might be associated with several factors, such as hypochlorhydria and hepcidin, in patients with GHP or NG.
- 17 September 2014
- Published by Springer Nature in Clinical Journal of Gastroenterology
- Vol. 7 (5) , 381-386
Clinical features and management of type I gastric carcinoids
Type I gastric carcinoids (TIGCs) are related to chronic atrophic gastritis and are characterized by hypergastrinemia and hyperplasia of enterochromaffin-like cells. TIGCs are the most frequently diagnosed of all gastric carcinoids, accounting for about 70–80 %. Endoscopically, TIGCs are present as small (<10 mm), polypoid lesions or, more frequently, as smooth, rounded submucosal lesions. Histologically, TIGCs arise in the deep mucosa, with some invading the submucosa. Most TIGCs are well-differentiated tumors, with metastasis being rare. Therefore, patients with TIGCs generally have an excellent prognosis. Among the currently available treatment options are total gastrectomy, partial resection, antrectomy, endoscopic resection, and endoscopic surveillance, although no consensus has been reached on their optimal management. Further studies are needed to develop better management options for patients with TIGC.
- 17 September 2014
- Published by Springer Nature in Clinical Journal of Gastroenterology
- Vol. 7 (5) , 381-386
Clinical features and management of type I gastric carcinoids
Type I gastric carcinoids (TIGCs) are related to chronic atrophic gastritis and are characterized by hypergastrinemia and hyperplasia of enterochromaffin-like cells. TIGCs are the most frequently diagnosed of all gastric carcinoids, accounting for about 70–80 %. Endoscopically, TIGCs are present as small (<10 mm), polypoid lesions or, more frequently, as smooth, rounded submucosal lesions. Histologically, TIGCs arise in the deep mucosa, with some invading the submucosa. Most TIGCs are well-differentiated tumors, with metastasis being rare. Therefore, patients with TIGCs generally have an excellent prognosis. Among the currently available treatment options are total gastrectomy, partial resection, antrectomy, endoscopic resection, and endoscopic surveillance, although no consensus has been reached on their optimal management. Further studies are needed to develop better management options for patients with TIGC.
- 5 November 2013
- Published by Wiley in Digestive Endoscopy
- Vol. 26 (3) , 377-384
Management and clinical outcomes of type I gastric carcinoid patients: Retrospective, multicenter study in Japan
Background and Aim: Type I gastric carcinoids (TIGC) are associated with chronic atrophic gastritis (CAG) with hypergastrinemia and hyperplasia of enterochromaffin‐like cells. Several treatment options are currently available for these tumors including total gastrectomy, partial resection, antrectomy, endoscopic resection and endoscopic surveillance. The present study evaluated different treatment approaches and clinical outcomes of patients with TIGC in Japan.Methods: Between 1991 and 2011, 82 patients with TIGC were identified at multicenter institutions in Japan. Patient demographics, tumor size, depth of invasion, vessel involvement, treatment approach, Helicobacter pylori infection, serum gastrin level, recurrence‐free survival (RFS) and disease‐specific survival (DSS) were analyzed.Results: Median age of all patients at the time of diagnosis was 56 years (range, 24−79 years). There were 44 males and 38females. Patients underwent endoscopic surveillance (n = 25), endoscopic resection (n = 41) or surgical resection (n = 16). Intramucosal invasion was found in 19 patients, submucosal invasion in 44 patients and muscularis propria invasion in one patient. Tumor diameter was ≤10 mm in 71 patients, 11–20 mm in five patients and ≥21 mm in five patients. None of the patients showed rapidly growing tumors, local recurrence or metastasis. The median (range) follow‐up period was 7 (0–20) years. RFS was 97.6% and DSS was 100% in all the patients.Conclusion: The prognosis of TIGC patients treated by different modalities in Japan is favorable regardless of the generational change of management for TIGC.
- 5 November 2013
- Published by Wiley in Digestive Endoscopy
- Vol. 26 (3) , 377-384
Management and clinical outcomes of type I gastric carcinoid patients: Retrospective, multicenter study in Japan
Background and Aim: Type I gastric carcinoids (TIGC) are associated with chronic atrophic gastritis (CAG) with hypergastrinemia and hyperplasia of enterochromaffin‐like cells. Several treatment options are currently available for these tumors including total gastrectomy, partial resection, antrectomy, endoscopic resection and endoscopic surveillance. The present study evaluated different treatment approaches and clinical outcomes of patients with TIGC in Japan.Methods: Between 1991 and 2011, 82 patients with TIGC were identified at multicenter institutions in Japan. Patient demographics, tumor size, depth of invasion, vessel involvement, treatment approach, Helicobacter pylori infection, serum gastrin level, recurrence‐free survival (RFS) and disease‐specific survival (DSS) were analyzed.Results: Median age of all patients at the time of diagnosis was 56 years (range, 24−79 years). There were 44 males and 38females. Patients underwent endoscopic surveillance (n = 25), endoscopic resection (n = 41) or surgical resection (n = 16). Intramucosal invasion was found in 19 patients, submucosal invasion in 44 patients and muscularis propria invasion in one patient. Tumor diameter was ≤10 mm in 71 patients, 11–20 mm in five patients and ≥21 mm in five patients. None of the patients showed rapidly growing tumors, local recurrence or metastasis. The median (range) follow‐up period was 7 (0–20) years. RFS was 97.6% and DSS was 100% in all the patients.Conclusion: The prognosis of TIGC patients treated by different modalities in Japan is favorable regardless of the generational change of management for TIGC.